Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

The Medicines Company Buys A German Firm

August 11, 2008 | A version of this story appeared in Volume 86, Issue 32

The Medicines Co. has acquired Germany's Curacyte Discovery and its lead compound, CU-2010, a small-molecule serine protease inhibitor that is being developed for the prevention of surgical blood loss. TMC, based in Parsippany, N.J., paid about $22 million and will make an additional payment of about $16 million to Curacyte's owners if CU-2010 makes it to Phase II clinical trials. TMC expects Phase I testing to start later this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.